Why Portola’s Stock Decline
Everybody interested in Portola (PTLA) knows by now that this firm has managed to put two FDA-approved products on the market.
They are:
Bevyxxa® (betrixaban): The first and only once-daily oral Factor Xa inhibitor, for the prevention of deep vein thrombosis (DVT), that subject them to venous thromboembolism (VTE), which could have life-threatening lung embolism.

Andexxa®: The first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to . . .